Today: June 21, 2018, 7:46 pm
  
Business

Karolinska Development will receive shares in Pharmanest AB

PR-Inside.com: 2017-11-09 14:48:01

STOCKHOLM - November 9, 2017. Karolinska Development today announces that the company will receive 140,149 shares in Pharmanest AB. Furthermore, the company will receive 11,527 shares via KCIF Co-Investment Fund. In total, this corresponds to an ownership of 10,4 percent in Pharmanest. Pharmanest is one of the companies covered by Karolinska Development's earn out-agreements. The transaction requires approval at the general meeting at Pharmanest.

Pharmanest develops a new and innovative treatment of pain in conjunction with gynaecological procedures, based on its unique technology platform SHACT. The company recently entered a license agreement with the pharmaceutical company Gedeon Richter Plc. This agreement gives Gedeon Richter the right to commercialize Pharmanest's SHACT technology in Europe, Latin America and other specific geographies.

Karolinska Development will receive 140,149 shares in Pharmanest. Moreover, Karolinska development will receive 11,527 shares via KCIF Co-Investment Fund KB, a holding company jointly owned by the European Investment Fund and Karolinska Development.

"The ownership in Pharmanest AB has a positive impact on our overall portfolio value and we look forward to following the company's future development. This is yet another confirmation of the value in the earn-out agreements we have signed in conjunction with divestments", says Viktor Drvota, CEO, Karolinska Development.
For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 2.45 pm CET on 9 of November 2017. 

Pharmanest shares (ENG)



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire




# 644 Words
Related Articles
More From The Author
Abeona Enrolls First Subject in Spain in [..]
Company Opens European Subsidiary in Spain to Support Global Clinical Development Nine subjects at global clinical sites enrolled [..]
Atos identified as a Leader in Next-Generation [..]
Paris, November 9 2017 - Atos, a global leader in digital transformation, was among the select companies that Forrester invited [..]
Hiab presents the world's first electric powered [..]
CARGOTEC CORPORATION, PRESS RELEASE, 9 NOVEMBER 2017 AT 3 PM EET   Hiab, part of Cargotec, presented  the world's first [..]
Disruptive Semiconductor Technology Leader Luxcore Signs [..]
Luxcore selects INAP to support their ground breaking second generation LambdaRouterTM --- the first full wavelength optical router. [..]
Skyharbour Option Partner AREVA Resources Canada Announces [..]
VANCOUVER, British Columbia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the [..]
 
More From Business
Carrie Lam encourages French companies to leverage [..]
HONG KONG, June 20, 2018 - (ACN Newswire) - The Chief Executive of the Hong Kong Special Administrative Region, Mrs [..]
Tarps Now® Expansion Focuses on Deliveries of [..]
ST. JOSEPH, MICHIGAN, UNITED STATES -- Tarps Now® is pleased to announce increased commitment to Heavy Duty Tarps and Covers [..]
Hong Kong Q2 2018 Exports Index at [..]
HONG KONG, June 20, 2018 - (ACN Newswire) - The HKTDC Export Index for the second quarter of 2018 (2Q18) [..]
Colorado Springs Movers Celebrates 21 Years Serving [..]
Moving Day Inc. is a Colorado Springs based moving company that is celebrating 21 years of serving clients by providing [..]
Apple Pay Coming to JCB's Customers in [..]
TOKYO, June 19, 2018 - (ACN Newswire) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd, [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.